Skip to main content
Equibles
XENE logo

XENE · Xenon Pharmaceuticals Inc. · Metrics

Track XENE — free

Use XENE with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research XENE.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$58.55 -0.25 (-0.43%)
Russell 2000 member Rebalance outlook locked
Market Cap
$5.71B
Shares
96.84M

XENE metrics

57 of 115 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$58.80
Market cap
$5.71B

Price action

20 metrics
Price change (1W)
-2.0%
Price change (30D)
-6.7%
Price change (3M)
+14.9%
Price change (6M)
-0.1%
Price change (YTD)
+31.6%
Price change (1Y)
+57.2%
Trailing year
Price change (5Y)
+229.3%
52-week high
$70.96
52-week low
$35.66
Change from 52-week high
-16.9%
Change from 52-week low
+65.4%
Annualized volatility
60.2%
Annualized volatility (3M)
38.2%
Beta
0.9
RSI (14D)
39.5
Price vs SMA 50
-7.1%
Price vs SMA 200
+11.3%
Avg volume (3M)
1.12M
Relative volume
0.4
Average dollar volume
$69.18M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
96.84M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
4.6
reciprocal yield 21.8%
FCF yield
-5.9%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-7.2%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-08-06

Profitability

9 metrics
Gross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$441.59M
Net income (TTM)
−$409.19M
Trailing 12 months
Diluted EPS (TTM)
$-4.74
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$7.27

Growth

11 metrics
Revenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
$0
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+26.2%
Year over year · more shares
Revenue CAGR (3Y)
-7.4%
Revenue CAGR (5Y)
-25.3%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-32.9%
Return on assets
-31.6%
Debt / equity
—
Current ratio
21.0
EBITDA (TTM)
−$439.19M
Free cash flow (TTM)
−$338.53M
Quick ratio
21.0
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$119.53M
Total assets
$1.30B
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$337.52M
Capital expenditures (TTM)
$1.01M
R&D (TTM)
$352.49M
SG&A (TTM)
—
Stock compensation (TTM)
$61.45M
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

3 metrics
13F filers
317
13F filer change QoQ
+22
Institutional ownership
105.5%

Short interest

3 metrics
Short interest
6.6%
Latest settlement · 9.1 days to cover
Days to cover
9.1d
Short-squeeze score
70 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$1.07M
Insider-sentiment score
44 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 1582313 CUSIP 98420N105 13F (30d) 197 filings 197 filers Visit website Investor relations